Ding Zhaohui, Deng Youlin, Luo Huie, Liu Cuiwang, Yang Minjuan, Xue Hanrong, Chen Zhengtao
Department of Clinical Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Front Pharmacol. 2025 Feb 24;16:1505672. doi: 10.3389/fphar.2025.1505672. eCollection 2025.
The respiratory system stands as one of the eight pivotal systems within the human body, responsible for a range of essential functions. Primarily, it facilitates the absorption of oxygen from the external environment and the expulsion of carbon dioxide, thereby playing a crucial role in regulating the body's acid-base balance. Furthermore, it helps to maintain the stability of the internal environment, ensuring the smooth progression of normal metabolic processes and sustaining life activities. In the wake of the novel coronavirus pneumonia outbreak, respiratory diseases have continued to exhibit comparatively high morbidity and mortality rates, underscoring the urgent need for the discovery of novel therapeutic agents. Tanshinone IIA (Tan IIA), a bioactive chemical constituent derived from has emerged as a promising candidate. As a significant fat-soluble compound, Tan IIA has traditionally been utilized in the treatment of cardiovascular diseases. As research on Tan IIA has progressed, its multifaceted therapeutic potential has been unveiled. Specifically, Tan IIA has demonstrated anti-inflammatory, anti-oxidative stress, anti-fibrosis, and anti-cancer effects. In recent years, a wealth of studies has concentrated on elucidating its impact on various respiratory diseases, including asthma, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary fibrosis, acute lung injury/acute respiratory distress syndrome, and lung cancer. These findings collectively suggest that Tan IIA holds considerable promise in the realm of anti-respiratory disease therapies. The present article undertakes a comprehensive review of the targets and potential mechanisms of Tan IIA against respiratory diseases, offering valuable insights that can serve as a reference for future research endeavors and clinical applications of Tan IIA in the treatment of respiratory ailments.
呼吸系统是人体八大关键系统之一，负责一系列重要功能。它主要促进从外部环境中吸收氧气并排出二氧化碳，从而在调节人体酸碱平衡中发挥关键作用。此外，它有助于维持内环境的稳定，确保正常代谢过程的顺利进行并维持生命活动。在新型冠状病毒肺炎疫情爆发后，呼吸系统疾病的发病率和死亡率持续居高不下，凸显了发现新型治疗药物的迫切需求。丹参酮IIA（Tan IIA），一种从[具体来源未提及]中提取的生物活性化学成分，已成为一个有前景的候选药物。作为一种重要的脂溶性化合物，丹参酮IIA传统上一直用于治疗心血管疾病。随着对丹参酮IIA研究的进展，其多方面的治疗潜力已被揭示。具体而言，丹参酮IIA已显示出抗炎、抗氧化应激、抗纤维化和抗癌作用。近年来，大量研究集中于阐明其对各种呼吸系统疾病的影响，包括哮喘、慢性阻塞性肺疾病、肺动脉高压、肺纤维化、急性肺损伤/急性呼吸窘迫综合征和肺癌。这些发现共同表明，丹参酮IIA在抗呼吸系统疾病治疗领域具有相当大的潜力。本文对丹参酮IIA抗呼吸系统疾病的靶点和潜在机制进行了全面综述，提供了有价值的见解，可为丹参酮IIA治疗呼吸系统疾病的未来研究工作和临床应用提供参考。
